WO2010118367A3 - Pyrimidines antivirales - Google Patents
Pyrimidines antivirales Download PDFInfo
- Publication number
- WO2010118367A3 WO2010118367A3 PCT/US2010/030598 US2010030598W WO2010118367A3 WO 2010118367 A3 WO2010118367 A3 WO 2010118367A3 US 2010030598 W US2010030598 W US 2010030598W WO 2010118367 A3 WO2010118367 A3 WO 2010118367A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compounds
- infection
- pyrimidines
- pyrazolopyrimtdines
- virus
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention concerne de nouveaux composés comprenant des pyrimidines, des pyrazolopyrimidines, et des imidazolopyrimidines substituées, leurs synthèses, et des compositions les comprenant, y compris des compositions pharmaceutiques, comprenant les nouvelles pyrimidines, pyrazolopyrimidines, imidazolpyrimidines et des composés analogues. De tels composés fonctionnent en inhibant l'entrée des virus de la famille des Flaviviridae, y compris le virus de l'hépatite C (VHC), à l'intérieur des cellules qui sont susceptibles d'être infectées par les virus. Ces composés sont utiles dans le traitement, la thérapie et/ou la prophylaxie de maladies virales et d'infections, y compris l'infection par le VHC.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16832309P | 2009-04-10 | 2009-04-10 | |
US61/168,323 | 2009-04-10 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2010118367A2 WO2010118367A2 (fr) | 2010-10-14 |
WO2010118367A3 true WO2010118367A3 (fr) | 2011-03-10 |
Family
ID=42936895
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2010/030598 WO2010118367A2 (fr) | 2009-04-10 | 2010-04-09 | Pyrimidines antivirales |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2010118367A2 (fr) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8476431B2 (en) | 2008-11-03 | 2013-07-02 | Itellikine LLC | Benzoxazole kinase inhibitors and methods of use |
US8637542B2 (en) | 2008-03-14 | 2014-01-28 | Intellikine, Inc. | Kinase inhibitors and methods of use |
US8993580B2 (en) | 2008-03-14 | 2015-03-31 | Intellikine Llc | Benzothiazole kinase inhibitors and methods of use |
US9096611B2 (en) | 2008-07-08 | 2015-08-04 | Intellikine Llc | Kinase inhibitors and methods of use |
US9295673B2 (en) | 2011-02-23 | 2016-03-29 | Intellikine Llc | Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof |
US9359349B2 (en) | 2007-10-04 | 2016-06-07 | Intellikine Llc | Substituted quinazolines as kinase inhibitors |
Families Citing this family (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ597050A (en) | 2009-06-29 | 2014-02-28 | Incyte Corp | Pyrimidinones as pi3k inhibitors |
US8445490B2 (en) | 2009-10-14 | 2013-05-21 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
AU2010306803A1 (en) | 2009-10-14 | 2012-05-03 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
US8759359B2 (en) | 2009-12-18 | 2014-06-24 | Incyte Corporation | Substituted heteroaryl fused derivatives as PI3K inhibitors |
EP2558463A1 (fr) | 2010-04-14 | 2013-02-20 | Incyte Corporation | Dérivés condensés en tant qu'inhibiteurs de i3 |
EP2566872B1 (fr) | 2010-05-04 | 2014-12-24 | Bristol-Myers Squibb Company | Composés destinés au traitement de l'hépatite c |
WO2011163195A1 (fr) | 2010-06-21 | 2011-12-29 | Incyte Corporation | Dérivés condensés de pyrrole en tant qu'inhibiteurs de pi3k |
US8765944B2 (en) | 2010-08-19 | 2014-07-01 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
AR084366A1 (es) | 2010-12-20 | 2013-05-08 | Incyte Corp | N-(1-(fenil sustituido)etil)-9h-purin-6-aminas como inhibidores de pi3k |
US9108984B2 (en) | 2011-03-14 | 2015-08-18 | Incyte Corporation | Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors |
WO2012135009A1 (fr) | 2011-03-25 | 2012-10-04 | Incyte Corporation | Dérivés de pyrimidine-4,6-diamine en tant qu'inhibiteurs de pi3k |
US8933066B2 (en) | 2011-04-14 | 2015-01-13 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
BR112013026521A2 (pt) | 2011-04-21 | 2016-12-27 | Origenis Gmbh | pirazolo[4,3-d]pirimidinas úteis como inibidores de cinase |
BR122019020716B1 (pt) | 2011-09-02 | 2021-02-17 | Incyte Holdings Corporation | heterociclilaminas como inibidores de pi3k e composição farmacêutica que as compreende |
MD20140023A2 (ro) | 2011-09-22 | 2014-06-30 | Pfizer Inc. | Derivaţi de pirolpirimidină şi purină |
US8629150B2 (en) | 2011-09-28 | 2014-01-14 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
US8697706B2 (en) | 2011-10-14 | 2014-04-15 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
US8916702B2 (en) | 2012-02-06 | 2014-12-23 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
AR090548A1 (es) | 2012-04-02 | 2014-11-19 | Incyte Corp | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k |
RU2014151009A (ru) * | 2012-06-07 | 2016-08-10 | Ф. Хоффманн-Ля Рош Аг | Пиразолопиримидоновые и пиразолопиридоновые ингибиторы танкиразы |
CN102827085A (zh) * | 2012-09-17 | 2012-12-19 | 符爱清 | 2,4,5-三氯嘧啶化合物的制备方法 |
CN102952086B (zh) * | 2012-09-28 | 2013-08-28 | 天津科创医药中间体技术生产力促进有限公司 | 一种2-吗啉基取代嘧啶类化合物的制备方法 |
CN102887860B (zh) * | 2012-09-29 | 2015-07-01 | 上海泰坦科技有限公司 | 4-氯-6-三氟甲基嘧啶类化合物的制备方法 |
WO2014062636A1 (fr) | 2012-10-18 | 2014-04-24 | Bristol-Myers Squibb Company | Composés pour le traitement de l'hépatite c |
US9637491B2 (en) * | 2012-10-19 | 2017-05-02 | Origenis Gmbh | Pyrazolo[4,3-D]pyrimidines as kinase inhibitors |
ES2652514T3 (es) | 2012-11-08 | 2018-02-02 | Pfizer Inc. | Compuestos heteroaromáticos como ligandos de dopamina D1 |
PT2935269T (pt) * | 2012-12-20 | 2018-07-16 | Katholieke Univ Leuven K U Leuven R&D | Derivados de pirazolo-pirimidina terapeuticamente activos |
US9624245B2 (en) | 2013-02-07 | 2017-04-18 | Bristol-Myers Squibb Company | Macrocyclic compounds as HCV entry inhibitors |
EP2953953B1 (fr) | 2013-02-07 | 2017-11-15 | Bristol-Myers Squibb Company | Molécules macrocycliques utilisées en tant qu'inhibiteurs de la pénétration du vhc |
SI2964646T1 (sl) * | 2013-03-07 | 2017-08-31 | F. Hoffmann-La Roche Ag | Novi derivati pirazola |
EP2964655B1 (fr) | 2013-03-07 | 2018-04-25 | Bristol-Myers Squibb Company | Composés macrocycliques pour le traitement de l'hépatite c |
TWI629275B (zh) * | 2013-03-13 | 2018-07-11 | 賽諾菲公司 | N-(4-(氮雜吲唑-6-基)-苯基)-磺醯胺及其作為醫藥之用途 |
DK2991988T3 (en) | 2013-05-02 | 2017-08-21 | Hoffmann La Roche | Pyrrolo [2,3-d] pyrimidine derivatives as CB2 receptor agonists |
JP6513636B2 (ja) | 2013-05-02 | 2019-05-15 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Cb2受容体アゴニストとしてのプリン誘導体 |
EP3020829B1 (fr) | 2013-07-12 | 2021-11-17 | Kyoto University | Composition pharmaceutique capable d'inhiber l'épissage anormal provoquant l'apparition ou l'évolution d'une maladie génétique |
ES2739435T3 (es) * | 2013-10-18 | 2020-01-31 | Univ Indiana Res & Tech Corp | Efectores del ensamblaje viral de la hepatitis B |
UA115388C2 (uk) | 2013-11-21 | 2017-10-25 | Пфайзер Інк. | 2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань |
WO2015123365A1 (fr) | 2014-02-11 | 2015-08-20 | Mitokinin Llc | Compositions et procedes les utilisant pour le traitement de maladie neurodegenerative et mitochondriale |
TN2016000452A1 (en) | 2014-04-25 | 2018-04-04 | Pfizer | Heteroaromatic compounds and their use as dopamine d1 ligands. |
EP3134405B1 (fr) | 2014-04-25 | 2019-08-28 | Pfizer Inc | Composes hetero-aromatiques et leur utilisation comme ligands d1 de la dopamine |
US10077277B2 (en) | 2014-06-11 | 2018-09-18 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors |
PT3244891T (pt) | 2015-01-16 | 2022-10-20 | Massachusetts Gen Hospital | Compostos para melhorar o splicing do arnm |
MD3262046T2 (ro) | 2015-02-27 | 2021-03-31 | Incyte Corp | Săruri de inhibitori ai PI3K și procedee pentru prepararea lor |
WO2016168619A1 (fr) | 2015-04-17 | 2016-10-20 | Indiana University Research And Technology Corporation | Effecteurs d'assemblage de virus de l'hépatite b |
US9732097B2 (en) | 2015-05-11 | 2017-08-15 | Incyte Corporation | Process for the synthesis of a phosphoinositide 3-kinase inhibitor |
WO2016183063A1 (fr) | 2015-05-11 | 2016-11-17 | Incyte Corporation | Formes cristallines d'un inhibiteur de pi3k |
US20180072718A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
CN109923114B (zh) | 2016-09-09 | 2022-11-01 | 因赛特公司 | 作为hpk1调节剂的吡唑并吡啶衍生物和其用于治疗癌症的用途 |
US20180072741A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyrimidine compounds and uses thereof |
US10280164B2 (en) | 2016-09-09 | 2019-05-07 | Incyte Corporation | Pyrazolopyridone compounds and uses thereof |
WO2018064135A1 (fr) * | 2016-09-30 | 2018-04-05 | Asana Biosciences, Llc | Composés p2x3 et/ou p2x2/3 et méthodes associées |
WO2018152220A1 (fr) | 2017-02-15 | 2018-08-23 | Incyte Corporation | Composés de pyrazolopyridine et leurs utilisations |
WO2018151326A1 (fr) | 2017-02-20 | 2018-08-23 | 国立大学法人京都大学 | Composition pharmaceutique et méthode de traitement pour une maladie génétique associée à des anomalies d'épissage |
CN107383014B (zh) * | 2017-06-21 | 2019-04-30 | 南方医科大学 | 一种1H-吡唑并[3,4-d]嘧啶类化合物及其制备方法和应用 |
WO2018237145A1 (fr) | 2017-06-21 | 2018-12-27 | Mitokinin, Inc. | Compositions et méthodes les utilisant pour le traitement d'une maladie neurodégénérative et mitochondriale |
CN109384782A (zh) * | 2017-08-04 | 2019-02-26 | 厦门大学 | 取代五元并六元杂环类化合物、其制备方法、药物组合及其用途 |
WO2019051199A1 (fr) | 2017-09-08 | 2019-03-14 | Incyte Corporation | Composés de 6-cyano-indazole utilisés en tant que modulateurs de kinase 1 progénitrices hématopoïétiques (hpk1) |
IL274444B1 (en) | 2017-11-06 | 2024-02-01 | Rapt Therapeutics Inc | Chemokine receptor modulators for the treatment of Epstein-Barr virus-positive cancer |
WO2019164847A1 (fr) | 2018-02-20 | 2019-08-29 | Incyte Corporation | Composés d'indazole et leurs utilisations |
LT3755703T (lt) | 2018-02-20 | 2022-10-10 | Incyte Corporation | N-(fenil)-2-(fenil)pirimidin-4-karboksamido dariniai ir susiję junginiai, kaip hpk1 inhibitoriai, skirti vėžio gydymui |
US10745388B2 (en) | 2018-02-20 | 2020-08-18 | Incyte Corporation | Indazole compounds and uses thereof |
US11299473B2 (en) | 2018-04-13 | 2022-04-12 | Incyte Corporation | Benzimidazole and indole compounds and uses thereof |
US10899755B2 (en) | 2018-08-08 | 2021-01-26 | Incyte Corporation | Benzothiazole compounds and uses thereof |
EP3856348B1 (fr) | 2018-09-25 | 2024-01-03 | Incyte Corporation | Composés pyrazolo[4,3-d]pyrimidine en tant que modulateurs des alk2 et/ou fgfr |
WO2020063636A1 (fr) * | 2018-09-27 | 2020-04-02 | 苏州锐明新药研发有限公司 | Composé de pyrazolopyrimidine et son procédé de préparation et son utilisation dans la préparation d'un médicament anticancéreux |
CN110698432B (zh) * | 2018-11-07 | 2023-02-03 | 中国医学科学院医药生物技术研究所 | 苯甲基哌嗪类化合物及其制备方法和在抗病毒中的应用 |
CN111170992B (zh) * | 2018-11-12 | 2021-05-14 | 新发药业有限公司 | 一种5,6-二氢吡啶-2(1h)-酮衍生物的制备方法 |
WO2020117972A1 (fr) * | 2018-12-04 | 2020-06-11 | The Board Of Regents Of The University Of Texas System | Agents thérapeutiques ciblant la polypose adénomateuse colique (apc) mutante pour le traitement du cancer |
JP2022529052A (ja) * | 2019-04-18 | 2022-06-16 | ユニベルシテ・ド・リエージュ | グラム陰性細菌の感染、汚染、及びファウリングを予防及び治療するための新規ピリミジン誘導体 |
CN110437253A (zh) * | 2019-08-06 | 2019-11-12 | 复旦大学 | 含联苯结构的二芳基嘧啶并环化合物及其制备方法和用途 |
PE20221419A1 (es) | 2019-08-06 | 2022-09-20 | Incyte Corp | Formas solidas de un inhibidor de hpk1 |
EP4028133A1 (fr) | 2019-09-13 | 2022-07-20 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Inhibiteurs du récepteur de la tyrosine kinase pour le traitement de maladie ou de trouble sensible à la modulation de la protéine kinase |
EP3800188A1 (fr) | 2019-10-02 | 2021-04-07 | Bayer AG | Pyrazolopyrimidines substituées en tant qu'inhibiteurs d'irak4 |
WO2021102600A1 (fr) | 2019-11-29 | 2021-06-03 | 中国医学科学院医药生物技术研究所 | Composé de benzylpipérazine, son procédé de préparation et son application en antivirus |
CN111732575B (zh) * | 2020-08-03 | 2020-12-11 | 北京鑫开元医药科技有限公司 | 一种n-(3-(嘧啶-2-基)苯基)苯磺酰胺类衍生物、药物组合物、制备方法及应用 |
WO2022123310A1 (fr) * | 2020-12-11 | 2022-06-16 | Ildong Pharmaceutical Co., Ltd. | Nouveaux composés en tant qu'inhibiteurs doubles du récepteur des androgènes et de la phosphodiestérase |
CN113292452B (zh) * | 2021-06-01 | 2023-03-24 | 山东京博生物科技有限公司 | 一种氰基乙酰胺的合成方法 |
CN113979945A (zh) * | 2021-11-15 | 2022-01-28 | 湖北理工学院 | 一种制备3-氨基吡唑-4-甲酰胺半硫酸盐的新方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5478830A (en) * | 1992-05-29 | 1995-12-26 | The Du Pont Merck Pharmaceutical Company | Fused-ring heterocycles for the treatment of atherosclerosis |
JP2004506737A (ja) * | 2000-08-18 | 2004-03-04 | アグーロン ファーマシューティカルズ,インコーポレイテッド | ピラゾール化合物、薬剤組成物、およびerabまたはhadh2活性の調節または阻害方法 |
WO2005121107A1 (fr) * | 2004-06-09 | 2005-12-22 | F. Hoffmann-La Roche Ag | Pyrazolopyrimidines |
WO2006132460A1 (fr) * | 2005-06-10 | 2006-12-14 | Dong-A Pharmaceutical.Co., Ltd. | Agent pour la prevention et le traitement des maladies du foie contenant un derive de la pyrazolopyrimidine |
-
2010
- 2010-04-09 WO PCT/US2010/030598 patent/WO2010118367A2/fr active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5478830A (en) * | 1992-05-29 | 1995-12-26 | The Du Pont Merck Pharmaceutical Company | Fused-ring heterocycles for the treatment of atherosclerosis |
JP2004506737A (ja) * | 2000-08-18 | 2004-03-04 | アグーロン ファーマシューティカルズ,インコーポレイテッド | ピラゾール化合物、薬剤組成物、およびerabまたはhadh2活性の調節または阻害方法 |
WO2005121107A1 (fr) * | 2004-06-09 | 2005-12-22 | F. Hoffmann-La Roche Ag | Pyrazolopyrimidines |
WO2006132460A1 (fr) * | 2005-06-10 | 2006-12-14 | Dong-A Pharmaceutical.Co., Ltd. | Agent pour la prevention et le traitement des maladies du foie contenant un derive de la pyrazolopyrimidine |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9359349B2 (en) | 2007-10-04 | 2016-06-07 | Intellikine Llc | Substituted quinazolines as kinase inhibitors |
US8637542B2 (en) | 2008-03-14 | 2014-01-28 | Intellikine, Inc. | Kinase inhibitors and methods of use |
US8993580B2 (en) | 2008-03-14 | 2015-03-31 | Intellikine Llc | Benzothiazole kinase inhibitors and methods of use |
US9096611B2 (en) | 2008-07-08 | 2015-08-04 | Intellikine Llc | Kinase inhibitors and methods of use |
US8476431B2 (en) | 2008-11-03 | 2013-07-02 | Itellikine LLC | Benzoxazole kinase inhibitors and methods of use |
US8476282B2 (en) | 2008-11-03 | 2013-07-02 | Intellikine Llc | Benzoxazole kinase inhibitors and methods of use |
US9295673B2 (en) | 2011-02-23 | 2016-03-29 | Intellikine Llc | Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
WO2010118367A2 (fr) | 2010-10-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2010118367A3 (fr) | Pyrimidines antivirales | |
WO2009091388A3 (fr) | Triazines et composés associés présentant une activité antivirale, compositions et procédés associés | |
WO2011041713A3 (fr) | Agents anti-viraux à base de pipérazinyle | |
MX2010009563A (es) | Compuestos quimicos con accion antiviral contra virus de dengue y otros flavivirus. | |
MX2009012299A (es) | Farmacos antivirales para el tratamiento o prevencion de la infeccion del dengue. | |
WO2008133753A3 (fr) | Composés antiviraux | |
EA201390538A1 (ru) | Противовирусные соединения | |
EA201000556A1 (ru) | Спиропирролидины и их применение для борьбы с инфицированием посредством hcv (вирус гепатита с) и вич (вирус иммунодефицита человека) | |
WO2010081082A3 (fr) | Dérivés de phosphoramidate de composés guanosine nucléoside pour le traitement d'infections virales | |
PH12015500289A1 (en) | Anti-viral compounds | |
TN2012000214A1 (en) | Hepatitis c virus inhibitors | |
WO2012092484A3 (fr) | Nucléosides puriques substitués, dérivés phosphoramidate et phosphorodiamidate pour le traitement d'infections virales | |
MX2011008045A (es) | Inhibidores del virus de la hepatitis c. | |
TW200720285A (en) | Nucleoside compounds for treating viral infections | |
ATE475660T1 (de) | Antivirale verbindungen | |
WO2008021936A3 (fr) | Inhibiteurs du virus de l'hépatite c | |
WO2007041487A3 (fr) | Peptides inhibiteurs d'infections virales | |
WO2011106992A8 (fr) | Inhibiteurs de polymérase du virus de l'hépatite c ns5b | |
MX2011010905A (es) | Compuestos antivirales. | |
MX2010008749A (es) | Inhibidores del virus de la hepatitis c. | |
EA201000201A1 (ru) | Азотсодержащие бициклические химические вещества для лечения вирусных инфекций | |
WO2010055164A3 (fr) | Nouveaux inhibiteurs de la réplication de flavivirus | |
MX2009009473A (es) | Compuestos para el tratamiento de hepatitis c. | |
EA201370017A1 (ru) | Ингибиторы вируса гепатита с | |
AU2012332832A8 (en) | Compositions useful for the treatment of viral diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10762525 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 10762525 Country of ref document: EP Kind code of ref document: A2 |